DE3521733A1 - Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von tumoren und viruserkrankungen in niedriger dosierung - Google Patents
Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von tumoren und viruserkrankungen in niedriger dosierungInfo
- Publication number
- DE3521733A1 DE3521733A1 DE19853521733 DE3521733A DE3521733A1 DE 3521733 A1 DE3521733 A1 DE 3521733A1 DE 19853521733 DE19853521733 DE 19853521733 DE 3521733 A DE3521733 A DE 3521733A DE 3521733 A1 DE3521733 A1 DE 3521733A1
- Authority
- DE
- Germany
- Prior art keywords
- gamma
- use according
- ifn
- viral diseases
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 41
- 102000008070 Interferon-gamma Human genes 0.000 title claims abstract description 41
- 229960003130 interferon gamma Drugs 0.000 title claims abstract description 41
- 201000010099 disease Diseases 0.000 title claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
- 238000011282 treatment Methods 0.000 title claims abstract description 15
- 230000003612 virological effect Effects 0.000 title claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 11
- 230000009885 systemic effect Effects 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 28
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 12
- 102000014150 Interferons Human genes 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 9
- 229940047124 interferons Drugs 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 231100000632 Spindle poison Toxicity 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002212 purine nucleoside Substances 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000005303 weighing Methods 0.000 abstract 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 16
- 238000003745 diagnosis Methods 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- 102100026720 Interferon beta Human genes 0.000 description 10
- 108010047761 Interferon-alpha Proteins 0.000 description 10
- 102000006992 Interferon-alpha Human genes 0.000 description 10
- 108090000467 Interferon-beta Proteins 0.000 description 10
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000002642 intravenous therapy Methods 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
- 206010027458 Metastases to lung Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 206010063491 Herpes zoster oticus Diseases 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IOUUIFSIQMVYKP-UHFFFAOYSA-N Tetradecyl acetate Chemical compound CCCCCCCCCCCCCCOC(C)=O IOUUIFSIQMVYKP-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000011349 geniculate herpes zoster Diseases 0.000 description 2
- 230000002871 immunocytoma Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- PSOZMUMWCXLRKX-UHFFFAOYSA-N 2,4-dinitro-6-pentan-2-ylphenol Chemical compound CCCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O PSOZMUMWCXLRKX-UHFFFAOYSA-N 0.000 description 1
- VLHWNGXLXZPNOO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2-morpholin-4-ylethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CCN1CCOCC1 VLHWNGXLXZPNOO-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL76591A IL76591A0 (en) | 1984-10-05 | 1984-10-06 | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
| DE19853521733 DE3521733A1 (de) | 1985-06-18 | 1985-06-18 | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von tumoren und viruserkrankungen in niedriger dosierung |
| EP85111184A EP0181455B2 (de) | 1984-10-05 | 1985-09-04 | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur systemischen Behandlung von verschiedenen Erkrankungen des Menschen in niedriger Dosierung |
| DE8585111184T DE3583849D1 (de) | 1984-10-05 | 1985-09-04 | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung. |
| AT85111184T ATE66375T1 (de) | 1984-10-05 | 1985-09-04 | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung. |
| JP60218143A JP2662214B2 (ja) | 1984-10-05 | 1985-10-02 | 低投与量にてヒトの筋萎縮性側索硬化症を系統的に治療するためのγ―インターフェロン含有組成物 |
| DK198504524A DK174585B1 (da) | 1984-10-05 | 1985-10-04 | Anvendelse af gamma-inteferon til fremstilling af farmaceutiske præparater til systemisk behandling af forskellige sygdomme hos mennesker i lave doser |
| EP85112625A EP0177910A3 (de) | 1984-10-05 | 1985-10-04 | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur systemischen Behandlung von verschiedenen Erkrankungen des Menschen in niedriger Dosierung |
| IL76591A IL76591A (en) | 1984-10-05 | 1985-10-06 | Pharmaceutical compositions containing ifn-ypsilon for the treatment or prevention of malignant or viral diseases |
| CA000492377A CA1288694C (en) | 1984-10-05 | 1985-10-07 | Process for treatment of diseases |
| AU48412/85A AU588547C (en) | 1984-10-05 | 1985-10-07 | Process for treatment of diseases |
| US07/510,714 US5145677A (en) | 1984-10-05 | 1990-04-18 | Process for treatment of diseases |
| JP9061337A JP3048533B2 (ja) | 1984-10-05 | 1997-03-14 | 低投与量にてアレルギー疾患を系統的に治療するための組換えヒトγ−インタフェロン含有組成物 |
| JP10339113A JPH11255665A (ja) | 1984-10-05 | 1998-11-30 | 低投与量にて腫瘍性または新生組織性細胞増殖を系統的に治療するための組換えヒトγ―インタフェロン含有組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853521733 DE3521733A1 (de) | 1985-06-18 | 1985-06-18 | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von tumoren und viruserkrankungen in niedriger dosierung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3521733A1 true DE3521733A1 (de) | 1986-12-18 |
| DE3521733C2 DE3521733C2 (enrdf_load_stackoverflow) | 1991-04-11 |
Family
ID=6273515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19853521733 Granted DE3521733A1 (de) | 1984-10-05 | 1985-06-18 | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von tumoren und viruserkrankungen in niedriger dosierung |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3521733A1 (enrdf_load_stackoverflow) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3001585A1 (de) * | 1979-01-18 | 1980-07-31 | Ashida Shin | Verfahren zur herstellung von interferon typ ii und es enthaltende zubereitungen |
| EP0088540A2 (en) * | 1982-02-22 | 1983-09-14 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human immune interferon-like polypeptides |
| US4483849A (en) * | 1983-01-07 | 1984-11-20 | Carter William A | Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product |
| US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
-
1985
- 1985-06-18 DE DE19853521733 patent/DE3521733A1/de active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3001585A1 (de) * | 1979-01-18 | 1980-07-31 | Ashida Shin | Verfahren zur herstellung von interferon typ ii und es enthaltende zubereitungen |
| US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
| EP0088540A2 (en) * | 1982-02-22 | 1983-09-14 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human immune interferon-like polypeptides |
| US4483849A (en) * | 1983-01-07 | 1984-11-20 | Carter William A | Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product |
Non-Patent Citations (15)
| Title |
|---|
| ABB, J.: Internist 26, 103-108, 1985 * |
| ADOLF, G.R. in: Recombinat Interferons ?2? und New aspects in research and therapy. Abstracts. Oxford: Medical Education Services, 1985, 20-21 (gutachtlich: Symposium vom 17.Juni 1985) |
| C. Jablecki et al.: An. Neurol. 10, 82, 1981 * |
| C.R. Adolf in: Recombinant interferons ??2? and ? : new aspects, in research and therapie. Abstracts Oxford: Medical Education Services, 1985, S.20/21 (gutachtlich) |
| C.R. Adolf in: Recombinant interferons alpha¶2¶ and gamma : new aspects, in research and therapie. Abstracts Oxford: Medical Education Services, 1985, S.20/21 (gutachtlich) * |
| Czarniecki, C.W. et.al.: J. Virol. 49, 490-496, 1984 |
| H. Kirchner, H. Schelleckens: The Biology of the Interferon System, 1984, Elsevier Science, Publishers, Amsterdam, 1985, S.575-579 (gutachtlich) * |
| MORA, J.S. et.al.: Neurology 34[Suppl 1], 141, 1984 * |
| Münch. med. Wschr. 126(17), 28 u. 31, 1984 * |
| Münch. med. Wschr., 126 (17), 28-29, 1984 * |
| OSTHER, K. et.al.: The Biology of the Interferon System, 527-533, 1983 * |
| Praxis-Kurier v. 12. Mai 1982, S.10, Münch. med. Wschr. 126, 28, 1984 |
| Praxis-Kurier, 19, vom 12.05.82, S.10 * |
| VERVLIET, G. et.al.: Clin. exp. Immunol. 59, 391-397, 1985 * |
| WEIGENT, D.A. et.al.: Infect. Immun. 40, 35-38, 1983 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3521733C2 (enrdf_load_stackoverflow) | 1991-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0181455B1 (de) | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur systemischen Behandlung von verschiedenen Erkrankungen des Menschen in niedriger Dosierung | |
| EP0170843B1 (de) | Synergistische Mischungen von Interferonen und Tumor-Nekrose-Faktor | |
| DE3750106T2 (de) | Rekombinanter B-Zell-Differenzierungsfaktor. | |
| DE68926859T2 (de) | Natürlicher killerzellen-stimulationsfaktor | |
| DE69333321T2 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| DE60208692T2 (de) | Interleukin -18 mutantenproteine, deren herstellung und verwendung | |
| AU652030B2 (en) | Treatment of neoplastic disease with interleukin-10 | |
| CA2062763A1 (en) | Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same | |
| JPH01503354A (ja) | Ｉｌ‐６の製造および用途 | |
| DE69123361T2 (de) | Verwendung von interleukin-4 zur behandlung der festen tumoren | |
| DE3586826T2 (de) | Cdna-klone, kodierend fuer peptide mit der wirksamkeit eines menschlichen granulocyte-, makrophage- und eosinophilzellenwachstumsfaktors. | |
| DE69007744T2 (de) | Verwendung von Interleukin 2 zur Behandlung von Leukämien. | |
| CA1297005C (en) | Pharmaceutical agent for the treatment of myelogenous leukemia | |
| DE69816502T2 (de) | Ein Interleukin-18 enthaltender Agent, der Osteoclastzellen inhibiert | |
| EP0311616B1 (en) | Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases | |
| EP0180737B1 (de) | Verwendung von Interferon gamma (IFN-gamma) zur Herstellung von Präparationen zur Behandlung rheumatischer Erkrankungen | |
| EP0455726A1 (en) | Treatment of leukocyte dysfunction with gm-csf | |
| DE3608608A1 (de) | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von autoimmunerkrankungen, viruserkrankungen und malignen erkrankungen des menschen in niedriger dosierung | |
| DE69718911T2 (de) | Interleukin - 8 als antivirale- und antitumorwirkstoffe | |
| Crockett et al. | Side effects and toxicity of interferon in the treatment of recurrent respiratory papillomatosis | |
| DE3521733A1 (de) | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von tumoren und viruserkrankungen in niedriger dosierung | |
| DE69224786T2 (de) | Die Verwendung von Interleukin-6 zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Lymphocytic Leukemia und B-Zell Lymphoma. | |
| DE3531597A1 (de) | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen | |
| JP2662214B2 (ja) | 低投与量にてヒトの筋萎縮性側索硬化症を系統的に治療するためのγ―インターフェロン含有組成物 | |
| Bialas et al. | Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3546568 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3546568 |
|
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| 8365 | Fully valid after opposition proceedings | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: DR. RENTSCHLER BIOTECHNOLOGIE GMBH, 88471 LAUPHEIM |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, 55218 ING |